あなたもお好きかもしれません
Respiratory diseases, such as asthma, acute lung injury, and chronic obstructive pulmonary disease (COPD), affect millions worldwide and pose significant health challenges. As the prevalence of respiratory diseases continues to rise, there is an increasing demand for innovative therapies to address disease mechanisms and improve patient outcomes.
In 2024, notable advancements have been made in the treatment of respiratory diseases, particularly COPD and asthma. Ensifentrine, a selective PDE3/4 inhibitor, has shown promising results in reducing acute exacerbations in COPD patients. Dupilumab, an IL-4 receptor α antibody, has effectively reduced acute exacerbations in COPD patients with high eosinophil counts. Tezepelumab, a TSLP-targeting monoclonal antibody, has demonstrated efficacy in delaying exacerbations in both severe asthma and COPD.
At Biocytogen, we offer a range of advanced animal models for respiratory diseases. Our models provide a reliable platform forin vivoevaluation, enabling researchers to assess drug efficacy, understand disease progression, and accelerate the development of novel therapies.
TSLP/OVA-Induced Asthma Model in B-hTSLP/hTSLPR Mice
Efficacy evaluation of anti-human TSLP (tezepelumab) in the hTSLP/OVA-induced asthma model usingB-hTSLP/hTSLPR mice.
(A)The number ofCD45+ cells in BALF.(B)The number of eosinophils in BALF.(C)Eosinophil proportion among CD45+ cells. Sensitization with TSLP/OVA increased leukocyte infiltration and eosinophil content in the G2 model group vs. G1 control, confirming successful model establishment. Tezepelumab (in-house) treatment reduced CD45+ cells and eosinophils.(D)BALF TARC levels and(E)serum total IgE levels were measured by ELISA at study end.
H&E staining of lung tissue in asthmatic mice showed that, compared to the G1 untreated group, TSLP/OVA-treated G2 model mice exhibited asthma-related pathology, including mucus formation(a)and vascular and peribronchial mixed inflammatory cell infiltration(b). Tezepelumab (in-house) treatment reduced CD45+ cells and eosinophils.
OVA-Induced Asthma Model in B-hIL4/hIL4RA Mice
Efficacy evaluation of anti-human IL4RA (dupilumab) in the OVA-induced asthma model usingB-hIL4/hIL4RA mice.
LPS/PPE-Induced COPD Model
H&E staining of lung tissue.LPS/PPE (porcine pancreatic elastase) treatment induced parenchymal and airway inflammation. H&E-stained lung sections from LPS/PPE-treated mice show inflammatory foci (arrows) and emphysema (asterisks).
Respiratory-Related Mouse Models at Biocytogen (Partial List)
Contact us today to learn more about our respiratory disease models!
